晚期胃癌分子靶向药物治疗及免疫治疗新进展

New advances in molecular targeted drug therapy and immunotherapy for advanced gastric carcinoma

胃癌发病率及致死率逐年增加,严重威胁人类健康。早期胃癌起病隐匿,多数患者发现时已至中晚期,治疗效果差,预后差。近年来,分子靶向药物及免疫治疗的作用日益增加,促进晚期胃癌患者生存率及疾病缓解率进一步提高。本文在国内外研究基础上,对胃癌分子靶向治疗、免疫治疗方面相关研究进行综述,为晚期胃癌的治疗提供新思路。

The incidence and mortality of gastric carcinoma are increasing year by year and seriously threatening human health. The onset of early gastric carcinoma is insidious, and most patients are found to be at the middle or late stages, with poor therapeutic effect and poor prognosis. In recent years, molecular targeted drugs and immunotherapy have been playing an increasingly important role in the treatment of gastric carcinoma, and the survival rate and disease remission rate of patients with advanced gastric carcinoma are improving. Based on the research at home and abroad, this paper reviews the research on molecular targeted therapy and immunotherapy for gastric cancer, providing a new direction for the treatment of advanced gastric carcinoma.